Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ALEC - Alector, Inc.
Market Cap 550.12M P/E - EPS this Y -22.40% Ern Qtrly Grth -
Income -160.66M Forward P/E -2.80 EPS next Y 14.70% 50D Avg Chg -4.00%
Sales 55.27M PEG 0.23 EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book 3.01 EPS next 5Y -10.70% 52W High Chg -51.00%
Recommedations 2.10 Quick Ratio 3.41 Shares Outstanding 97.32M 52W Low Chg 17.00%
Insider Own 8.72% ROA -18.30% Shares Float 81.43M Beta 0.68
Inst Own 86.05% ROE -92.64% Shares Shorted/Prior 3.46M/3.68M Price 6.60
Gross Margin -246.51% Profit Margin -290.66% Avg. Volume 503,085 Target Price 13.75
Oper. Margin -302.37% Earnings Date Nov 5 Volume 397,963 Change -4.49%
Healthcare | Biotechnology | United States
About Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector, Inc. News
11/27/24 ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
11/27/24 Alector price target lowered to $7 from $35 at H.C. Wainwright
11/26/24 Alector stock drops after Alzheimer’s drug fails in Phase II trial
11/26/24 Alector turns to layoffs as Alzheimer’s drug fails
11/25/24 Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
11/14/24 Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
11/06/24 Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
11/06/24 Alector: Q3 Earnings Snapshot
11/06/24 Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
11/01/24 Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
10/30/24 Is Alector (NASDAQ:ALEC) In A Good Position To Deliver On Growth Plans?
09/19/24 Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
09/19/24 Alector (NASDAQ:ALEC) investors are sitting on a loss of 77% if they invested three years ago
09/17/24 Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
08/29/24 Alector to Participate in Upcoming Healthcare Conferences
06:19 PM Director Richard Scheller Sells 44,250 Shares of Alector Inc (ALEC)
08/09/24 Alector Second Quarter 2024 Earnings: Beats Expectations
08/07/24 Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
08/07/24 Alector: Q2 Earnings Snapshot
08/07/24 Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GRASSO MARC Chief Financial Offi.. Chief Financial Officer Dec 04 Sell 5.56 4,574 25,431 150,673 12/06/23
Romano Gary Chief Medical Office.. Chief Medical Officer Dec 04 Sell 5.56 5,035 27,995 202,314 12/06/23
Rosenthal Arnon Chief Executive Offi.. Chief Executive Officer Dec 04 Sell 5.56 23,831 132,500 2,019,217 12/06/23
Kenkare-Mitra Sara President and Head o.. President and Head of R&D Dec 04 Sell 5.56 12,519 69,606 329,016 12/06/23
Rosenthal Arnon Chief Executive Offi.. Chief Executive Officer Sep 05 Sell 5.1945 5,647 29,333 1,645,448 09/06/23
Kenkare-Mitra Sara President and Head o.. President and Head of R&D Sep 05 Sell 5.1943 6,214 32,277 177,935 09/06/23
Romano Gary Chief Medical Office.. Chief Medical Officer Sep 05 Sell 5.1942 2,771 14,393 99,349 09/06/23
GRASSO MARC Chief Financial Offi.. Chief Financial Officer Sep 05 Sell 5.1943 1,114 5,786 32,247 09/06/23
Kenkare-Mitra Sara President and Head o.. President and Head of R&D Jun 02 Sell 6.9037 4,092 28,250 184,149 06/05/23
GRASSO MARC Chief Financial Offi.. Chief Financial Officer Jun 02 Sell 6.9037 1,050 7,249 33,361 06/05/23
Romano Gary Chief Medical Office.. Chief Medical Officer Jun 02 Sell 6.9037 2,617 18,067 102,120 06/05/23
Rosenthal Arnon Chief Executive Offi.. Chief Executive Officer Jun 02 Sell 6.9037 5,255 36,279 1,651,095 06/05/23
Rosenthal Arnon Chief Executive Offi.. Chief Executive Officer Mar 03 Sell 6.22 15,186 94,457 1,656,350 03/21/23
Romano Gary Chief Medical Office.. Chief Medical Officer Dec 02 Sell 8.51 5,383 45,809 104,737 03/03/23
Kenkare-Mitra Sara President and Head o.. President and Head of R&D Mar 02 Sell 8.3185 10,124 84,216 188,241 03/03/23
GRASSO MARC Chief Financial Offi.. Chief Financial Officer Mar 02 Sell 8.3184 1,291 10,739 34,411 03/03/23
Rosenthal Arnon Chief Executive Offi.. Chief Executive Officer Mar 02 Sell 8.3178 5,849 48,651 1,628,546 03/03/23
Yaffe Kristine Director Director Sep 10 Option 18.10 2,000 36,200 2,000 01/31/23
Romano Gary Chief Medical Office.. Chief Medical Officer Sep 02 Sell 10.6202 2,177 23,120 90,073 09/07/22
King Robert Chief Development Of.. Chief Development Officer Sep 02 Sell 10.6205 176 1,869 529,295 09/07/22
King Robert Chief Development Of.. Chief Development Officer Mar 01 Sell 15.5679 287 4,468 528,404 03/03/22
SULIMAN SHEHNAAZ President and COO President and COO Dec 10 Option 17.23 150,000 2,584,500 177,598 12/14/21
SULIMAN SHEHNAAZ President and COO President and COO Dec 10 Sell 21.73 150,000 3,259,500 102,598 12/14/21
SULIMAN SHEHNAAZ President and COO President and COO Dec 08 Option 14.9 150,000 2,235,000 177,598 12/10/21
SULIMAN SHEHNAAZ President and COO President and COO Dec 08 Sell 22.94 150,000 3,441,000 102,598 12/10/21
Rosenthal Arnon Chief Executive Offi.. Chief Executive Officer Nov 10 Sell 25 110,000 2,750,000 1,972,875 11/12/21
Rosenthal Arnon Chief Executive Offi.. Chief Executive Officer Nov 04 Sell 25 200,000 5,000,000 682,500 11/08/21
Paul Robert Chief Medical Office.. Chief Medical Officer Mar 10 Option 9.15 19,175 175,451 232,894 03/10/21
Paul Robert Chief Medical Office.. Chief Medical Officer Mar 10 Sell 18.12 19,175 347,451 213,719 03/10/21
Paul Robert Chief Medical Office.. Chief Medical Officer Feb 11 Option 9.15 19,175 175,451 232,894 02/11/21
Paul Robert Chief Medical Office.. Chief Medical Officer Feb 11 Sell 20.81 19,175 399,032 213,719 02/11/21
Paul Robert Chief Medical Office.. Chief Medical Officer Jan 27 Option 9.15 57,308 524,368 241,027 01/27/21
Paul Robert Chief Medical Office.. Chief Medical Officer Jan 27 Sell 18 57,308 1,031,544 213,719 01/27/21
Paul Robert Chief Medical Office.. Chief Medical Officer Jan 21 Option 9.15 38,567 352,888 222,286 01/21/21
Paul Robert Chief Medical Office.. Chief Medical Officer Jan 21 Sell 18.06 38,567 696,520 213,719 01/21/21